OLAPARIB
olaparib 150 mg tablet, 56
OLAPARIB (12161C)
12161C
Manner of administration:Oral
Restriction
Indication: High grade stage III/IV epithelial ovarian, fallopian tube or primary peritoneal cancer
Treatment phase: Continuation of first-line maintenance therapy (BRCA1/2 gene mutation)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 2 | Max qty units: 112 | # of repeats: 5 | DPMQ: $6,632.44 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Lynparza | |||||